Otsuka Pakistan Limited resumes production after completing its annual maintenance, with shares rising 4.3%. Routine shutdown ensures operational efficiency and market reliability.
STOCKHOLM, Nov. 13, 2025 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that Leqembi (lecanemab) has been approved for once every four weeks intravenous ...
Panelists discuss how maintaining patients on effective single therapies for Crohn’s disease is preferable to switching between different mechanisms of action, while addressing access challenges ...
TOKYO and CAMBRIDGE, Mass., Sept. 28, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (BIIB) (Nasdaq ...
The U.S. Food and Drug Administration (FDA) has approved Leqembi Iqlik (lecanemab-irmb), an under-the-skin autoinjector formulation for maintenance dosing in early Alzheimer’s disease. The approval, ...
While the approval of Leqembi Iqlik bodes well for Biogen and Eisai’s planned application for a subcutaneous induction regimen next year, its financial impact remains “uncertain,” as potentially ...
NEW YORK – The US Food and Drug Administration has approved a subcutaneous version of Eisai and Biogen's anti-amyloid Alzheimer's disease drug Leqembi (lecanemab) as an ongoing maintenance treatment, ...
IRVING, Texas--(BUSINESS WIRE)--Vizient ® announced today the expansion of the Vizient Reserve Program to include IV fluids through a strategic partnership with Baxter, a leading global medtech ...
International recommendations advise against the use of intravenous rehydration therapy in children with severe acute malnutrition because of the concern about fluid overload, but evidence to support ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback